A new IMS Health report indicates the loss of patents by top-selling brand drugs during the period 2011 to 2014 may bring $70 billion in savings to the marketplace. Among the brand drugs that will soon face generic competition are the following:
- Pfizer’s cholesterol-reducing drug Lipitor
- Bristol’s and Sanofi’s blood-clot preventer Plavix
- Lilly’s schizophrenia drug Zyprexa
- Merck’s asthma treatment Singulair
To learn more about IMS Health’s report, read this article.
And don’t forget — unless you change your PBM contract terms to ensure that you — not your PBM — will realize the financial benefits from newly available generic drugs, you may never obtain your rightful savings. Read the articles under Topics 3 and 5 on our Videos and Articles page, and learn exactly what you need to do.